These results, like the ones of the present study, are in favor of the absence or at least the high rarity of HER2-overexpressing mammary carcinomas in dogs, but need to be confirmed by molecular methods, either in situ at the gene level (such as specific in situ hybridization) or by RNA expression in a large cohort. The gene discussed is ERBB2; the disease is breast carcinoma.